<DOC>
	<DOC>NCT00569946</DOC>
	<brief_summary>To investigate objective tumor response of AG-013736 for metastatic Renal Cell Cancer (mRCC)</brief_summary>
	<brief_title>Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients histologically diagnosed as metastatic renal cell cancer with a component of clear cell cancer. Patients who are refractory to cytokine therapy as 1st line. Patients who experienced nephrectomy. Patients with at least 1 target lesion, as defined by RECIST. Patients with no uncontrolled hypertension. Gastrointestinal abnormalities Current use or anticipated inability to avoid potent CYP3A4 inhibitors or CYP1A2/3A4 inducers. Active seizure disorder or evidence of brain metastases. Patients with hemoptysis.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>AG-013736</keyword>
	<keyword>RCC</keyword>
	<keyword>Phase 2</keyword>
</DOC>